|
|
||||||||
Cutting Edge |


,
* BioXell and
Istituto Ricerche Farmacologiche "Mario Negri," Milano, Italy; and
Anatomia Patologica II, Spedali Civili, and
Section of Immunology, Università degli Studi, Brescia, Italy
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
M-DCs are characterized by a monocytic morphology, express myeloid
markers like CD13 and CD33, the
2 integrin
CD11c, the stimulatory receptor Ig-like transcript 1 and low
levels of the IL-3R
-chain CD123 (5). Conversely, P-DCs
have a morphology resembling plasma cells, are devoid of myeloid
markers, express high levels of CD4, CD62 ligand (CD62L) and CD123
(6, 7). M-DCs produce high levels of IL-12
(8), while P-DCs produce high levels of IFN-
(7, 9).
The proper localization of DCs in secondary lymphoid organs and their recruitment at sites of inflammation in response to chemotactic stimuli are critical for an optimal immune response. We have reported that, despite a similar expression and modulation of chemokine receptors, circulating P-DCs, in contrast to M-DCs, fail to migrate in response to inflammatory chemokines, while both subsets respond to lymph node homing chemokines following CD40 ligation (10). These different migration programs underscore the distinct lineage of these DC subsets and point to their divergent roles in the induction and regulation of the immune response.
To further define functional properties of M-DCs and P-DCs able to shape immune responses, in the present study we have analyzed their chemokine production in response to bacterial, viral, and T cell-derived stimuli. The results indicate a selective production of homeostatic chemokines, like CC chemokine ligand (CCL)17 and CCL22, by blood M-DCs. In contrast, P-DCs show a preferential production of proinflammatory chemokines, such as CCL3, pointing to a differential capacity of these two DC subsets to recruit discrete leukocyte populations at sites of inflammation.
| Materials and Methods |
|---|
|
|
|---|
PBMCs were isolated from buffy coats by Ficoll gradient (Pharmacia Biotec, Uppsala, Sweden) and peripheral blood M-DCs and P-DCs were magnetically sorted with blood DC Ag (BDCA)-1 and BDCA-4 cell isolation kits (Miltenyi Biotec, Bergisch Gladbach, Germany), respectively, as described (11), to a purity of 9598% in both cases. Blood M-DCs and P-DCs (2 x 104 cells/well) were cultured as described (10) in medium containing 1000 U/ml recombinant human GM-CSF (Mielogen; Schering-Plough, Kenilworth, NJ) and 10 ng/ml IL-4 (BD PharMingen, San Diego, CA) or 20 ng/ml IL-3 (BD PharMingen), respectively. Cells were stimulated with 1 µg/ml LPS (Escherichia coli 0111:B4; Sigma-Aldrich, St. Louis, MO), 1:5000 Staphylococcus aureus Cowans I (Pansorbin cells; Calbiochem, San Diego, CA), CD154-transfected J558L cells at a ratio of 4:1, 6 µg/ml CpG oligonucleotide 2006 (MGW Biotech, Ebersberg, Germany), and 20 ng of hemagglutinin/ml inactivated influenza virus strain A/Moscow/10/99 (a kind gift from Dr. T. De Magistris, Istituto Superiore di Sanità, Rome, Italy). After 2472 h of culture, supernatants were collected and chemokine concentrations were measured by sandwich ELISA using Abs from R&D Systems (Minneapolis, MN).
Flow cytometric analysis
Flow cytometric analysis was performed as previously described (12), in the presence of 100 µg/ml mouse IgG, using the mAbs anti-CD1c (BDCA-1) FITC or PE, and anti-BDCA-2 FITC or PE (Miltenyi Biotec). Cells were analyzed with a FACScan flow cytometer (BD Biosciences, Mountain View, CA) using CellQuest software.
Chemotaxis of L1.2 hCCR4 cells
L1.2 cells transfected with human CCR4 were kindly provided by Dr. D. DAmbrosio (BioXell, Milan, Italy). Chemotaxis assay was performed using 5-µm pore polyvinylpyrrolidone-free polycarbonate filters of 12-well transwell chambers (Corning Costar, Cambridge, MA). L1.2 hCCR4 cells were cultured for 16 h with 5 mM sodium butyrate, washed, and resuspended at a concentration of 1 x 106/ml in RPMI 1640 with 1% FCS. Supernatants from DC cultures or recombinant chemokines (0.6 ml) were added to the bottom chamber of the transwell and 0.1 ml of cell suspension was added to the top chamber. Transmigrated cells were recovered from the lower compartment of the transwell after a 3-h migration was performed at 37°C, and were quantified by trypan blue exclusion counting using light microscopy.
Immunohistology
CCL17 and CCL22 expression were evaluated on frozen sections from lymph nodes showing nonspecific reactive changes, using polyclonal goat anti-CCL17 Ab (Santa Cruz Biotechnology, Santa Cruz, CA) and a anti-CCL22 mAb kindly donated by Dr. P. Gray (ICOS, Bothell, WA). M-DCs and P-DCs were identified with anti-CD11c (BD Biosciences) and anti-CD123 (BD PharMingen), respectively. Immunohistochemistry was performed using the labeled streptavidin biotin system-HRP indirect immunoperoxidase technique (DAKO, Milan, Italy). Double immunofluorescence for CCL17 and CD11c was performed by applying anti-CCL17, followed by biotinylated rabbit anti-goat (Biogenex, San Ramon, CA) and Texas Red-conjugated streptavidin (Vector Laboratories, Burlingame, CA); after a 10-min incubation with normal goat serum, sections were treated with anti-CD11c and goat-anti-mouse IgG2b conjugated with FITC (Southern Biotechnology Associates, Birmingham, AL).
| Results |
|---|
|
|
|---|
Peripheral blood DCs from healthy donors were magnetically
purified based on the expression of BDCA-4, followed by B cell
depletion and selection of BCDA-1+ cells, as
described (11). As shown in Fig. 1
, two discrete populations, both
HLA-DR+ (data not shown) were obtained:
expressing CD1c and negative for BDCA-2 expression (M-DCs), or
expressing BDCA-2 (and BDCA-4, not shown) and negative for CD1c
expression (P-DCs). Additional phenotypic analysis of the purified
populations demonstrated that M-DCs were CD11c+,
CD123low, CD62Llow,
CD36low, and CD45
RAlow, whereas P-DCs were
CD11c-, CD123high,
CD62Lhigh, CD36high, and
CD45 RAhigh (data not shown), confirming the
subset assignment (7).
|
is mostly produced by P-DCs, whereas CCL4/MIP-1
and CXC
chemokine ligand (CXCL)8/IL-8 were produced at similar levels by both
subsets. Neither P-DCs nor M-DCs produced CCL1/I-309,
CCL2/monocyte chemoattractant protein-1, CCL5/RANTES, CCL18/pulmonary
and activation-regulated chemokine, CCL19/MIP-3
, or
CXCL12/stromal cell-derived factor-11, and only minimal levels
of CXCL10/IFN-
-inducible protein-10 were produced (Fig. 2
was also not produced under any condition tested (data
not shown). To ascertain whether the high levels of CCL22 and CCL17
produced by M-DCs were functional, culture supernatants were tested for
their capacity to induce the migration of CCR4-transfected cells.
Results in Fig. 3
|
|
To confirm in vivo the selective production of CCL22 and CCL17 by
M-DCs, their in situ production by reactive lymph node cells was
examined by immunohistochemistry (Fig. 4
). M-DCs, corresponding to
interdigitating reticulum cells, and P-DCs were identified on frozen
section from reactive lymph nodes with anti-CD11c and
anti-CD123 mAbs, respectively. On subserial sections, staining with
anti-CCL22 and anti-CCL17 showed cytoplasmic expression of both
molecules by M-DCs. Fig. 4
also shows a cell strongly positive for
CCL22 production and with dendritic morphology forming a rosette with
nearby lymphocytes. Double immunofluorescence revealed
CD11c+CCL17+ cells with
dendritic morphology. In contrast, P-DCs were uniformly negative for
expression of CCL22 and CCL17. The endothelium of a high endothelial
venule expressed CCL17, as previously reported in skin endothelial
cells (16). Therefore, CCL22 and CCL17 are selectively
produced by M-DCs, but not by P-DCs, also in vivo.
|
| Discussion |
|---|
|
|
|---|
Several chemokines, including CCL1, CCL2, CCL5, CCL18, CCL19, CCL20, and CXCL12 were not produced by either DC subset in response to any stimulus tested. In particular, CCL18, a chemokine reported to be produced in a constitutive manner by monocyte-derived DCs (27), was not detectably secreted by either blood DC subset, in both unstimulated and stimulated conditions. These results differ from a previous study where CCL18 was detected in activated CD11c+ blood DCs (28), and suggest that different stages of differentiation and/or of activation may modulate CCL18 production in DC subsets. Also CCL1, a chemokine able to recruit Th2 (29) and T regulatory (20, 21) cells was not produced under any condition tested.
Thus, similarly to what is observed in monocyte-derived DCs (17, 28), CCL17 and CCL22 are secreted in consistent levels by blood M-DCs and their production is strongly up-regulated following in vitro maturation. In contrast, neither circulating P-DCs nor P-DCs stimulated by CD40 ligation or by CpG secrete relevant levels of these two homeostatic chemokines. The migration behavior is also very different in the two cell types; circulating M-DCs migrate to several inflammatory chemokines in contrast to P-DCs responding only to the homeostatic chemokine CXCL12 (10). This would explain why P-DCs localize predominantly in secondary lymphoid organs, while M-DCs are rapidly recruited at sites of inflammation.
In conclusion, P-DCs produce preferentially proinflammatory chemokines but respond selectively to homeostatic ones whereas the reverse is true for M-DCs, highlighting not only the different migratory properties of these DC subsets but also their capacity to recruit different cell types at inflammation sites, and indicating a complementarity in their functional activity also in this respect.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Luciano Adorini, BioXell, Via Olgettina 58, I-20132 Milano, Italy. E-mail address: Luciano.Adorini{at}bioxell.com ![]()
3 Abbreviations used in this paper: DC, dendritic cell; M-DC, myeloid DC; P-DC, plasmacytoid DC; L, ligand; CCL, CC chemokine ligand; rh, recombinant human; BDCA, blood DC Ag; TLR, Toll-like receptor; MIP, macrophage-inflammatory protein; CXCL, CXC chemokine ligand. ![]()
Received for publication August 7, 2002. Accepted for publication October 10, 2002.
| References |
|---|
|
|
|---|
,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 164:2405.This article has been cited by other articles:
![]() |
W. N. Haining, J. Davies, H. Kanzler, L. Drury, T. Brenn, J. Evans, J. Angelosanto, S. Rivoli, K. Russell, S. George, et al. CpG Oligodeoxynucleotides Alter Lymphocyte and Dendritic Cell Trafficking in Humans Clin. Cancer Res., September 1, 2008; 14(17): 5626 - 5634. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Jin, S. Kavikondala, L. Sun, R. Fu, M.-Y. Mok, A. Chan, J. Yeung, and C.-S. Lau Systemic lupus erythematosus patients have increased number of circulating plasmacytoid dendritic cells, but decreased myeloid dendritic cells with deficient CD83 expression Lupus, July 1, 2008; 17(7): 654 - 662. [Abstract] [PDF] |
||||
![]() |
Z. Guo, M. H. Jang, K. Otani, Z. Bai, E. Umemoto, M. Matsumoto, M. Nishiyama, M. Yamasaki, S. Ueha, K. Matsushima, et al. CD4+CD25+ regulatory T cells in the small intestinal lamina propria show an effector/memory phenotype Int. Immunol., March 1, 2008; 20(3): 307 - 315. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Decalf, S. Fernandes, R. Longman, M. Ahloulay, F. Audat, F. Lefrerre, C. M. Rice, S. Pol, and M. L. Albert Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients J. Exp. Med., October 1, 2007; 204(10): 2423 - 2437. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Kim, N. R. Bianco, W. J. Shufesky, A. E. Morelli, and P. D. Robbins Effective Treatment of Inflammatory Disease Models with Exosomes Derived from Dendritic Cells Genetically Modified to Express IL-4 J. Immunol., August 15, 2007; 179(4): 2242 - 2249. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Beaty, C. E. Rose Jr., and S.-s. J. Sung Diverse and Potent Chemokine Production by Lung CD11bhigh Dendritic Cells in Homeostasis and in Allergic Lung Inflammation J. Immunol., February 1, 2007; 178(3): 1882 - 1895. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Penna, S. Amuchastegui, N. Giarratana, K. C. Daniel, M. Vulcano, S. Sozzani, and L. Adorini 1,25-Dihydroxyvitamin D3 Selectively Modulates Tolerogenic Properties in Myeloid but Not Plasmacytoid Dendritic Cells J. Immunol., January 1, 2007; 178(1): 145 - 153. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hosmalin and P. Lebon Type I interferon production in HIV-infected patients J. Leukoc. Biol., November 1, 2006; 80(5): 984 - 993. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Fanning, T. C. George, D. Feng, S. B. Feldman, N. J. Megjugorac, A. G. Izaguirre, and P. Fitzgerald-Bocarsly Receptor Cross-Linking on Human Plasmacytoid Dendritic Cells Leads to the Regulation of IFN-{alpha} Production J. Immunol., November 1, 2006; 177(9): 5829 - 5839. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Ding, H. Mehta, W. J. McCune, and M. J. Kaplan Aberrant Phenotype and Function of Myeloid Dendritic Cells in Systemic Lupus Erythematosus J. Immunol., November 1, 2006; 177(9): 5878 - 5889. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Osawa, S. Iho, R. Takauji, H. Takatsuka, S. Yamamoto, T. Takahashi, S. Horiguchi, Y. Urasaki, T. Matsuki, and S. Fujieda Collaborative Action of NF-{kappa}B and p38 MAPK Is Involved in CpG DNA-Induced IFN-{alpha} and Chemokine Production in Human Plasmacytoid Dendritic Cells J. Immunol., October 1, 2006; 177(7): 4841 - 4852. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Groot, T. M. M. van Capel, M. L. Kapsenberg, B. Berkhout, and E. C. de Jong Opposing roles of blood myeloid and plasmacytoid dendritic cells in HIV-1 infection of T cells: transmission facilitation versus replication inhibition Blood, September 15, 2006; 108(6): 1957 - 1964. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Chen, M. Arora, M. Yarlagadda, T. B. Oriss, N. Krishnamoorthy, A. Ray, and P. Ray Distinct Responses of Lung and Spleen Dendritic Cells to the TLR9 Agonist CpG Oligodeoxynucleotide J. Immunol., August 15, 2006; 177(4): 2373 - 2383. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Piqueras, J. Connolly, H. Freitas, A. K. Palucka, and J. Banchereau Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors Blood, April 1, 2006; 107(7): 2613 - 2618. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Infantino, B. Moepps, and M. Thelen Expression and Regulation of the Orphan Receptor RDC1 and Its Putative Ligand in Human Dendritic and B Cells J. Immunol., February 15, 2006; 176(4): 2197 - 2207. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Nicolo, G. Di Sante, M. Orsini, S. Rolla, S. Columba-Cabezas, V. R. Spica, G. Ricciardi, B. M. C. Chan, and F. Ria Mycobacterium tuberculosis in the adjuvant modulates the balance of Th immune response to self-antigen of the CNS without influencing a "core" repertoire of specific T cells Int. Immunol., February 1, 2006; 18(2): 363 - 374. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Del Corno, M. C. Gauzzi, G. Penna, F. Belardelli, L. Adorini, and S. Gessani Human Immunodeficiency Virus Type 1 gp120 and Other Activation Stimuli Are Highly Effective in Triggering Alpha Interferon and CC Chemokine Production in Circulating Plasmacytoid but Not Myeloid Dendritic Cells J. Virol., October 1, 2005; 79(19): 12597 - 12601. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Bendriss-Vermare, S. Burg, H. Kanzler, L. Chaperot, T. Duhen, O. de Bouteiller, M. D'agostini, J.-M. Bridon, I. Durand, J. M. Sederstrom, et al. Virus overrides the propensity of human CD40L-activated plasmacytoid dendritic cells to produce Th2 mediators through synergistic induction of IFN-{gamma} and Th1 chemokine production J. Leukoc. Biol., October 1, 2005; 78(4): 954 - 966. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Fuchs, M. Cella, T. Kondo, and M. Colonna Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44 Blood, September 15, 2005; 106(6): 2076 - 2082. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Urosevic, R. Dummer, C. Conrad, M. Beyeler, E. Laine, G. Burg, and M. Gilliet Disease-Independent Skin Recruitment and Activation of Plasmacytoid Predendritic Cells Following Imiquimod Treatment J Natl Cancer Inst, August 3, 2005; 97(15): 1143 - 1153. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Schutyser, A. Richmond, and J. Van Damme Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes J. Leukoc. Biol., July 1, 2005; 78(1): 14 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Tabata, N. Kadowaki, T. Kitawaki, T. Shimaoka, S. Yonehara, O. Yoshie, and T. Uchiyama Distribution and kinetics of SR-PSOX/CXCL16 and CXCR6 expression on human dendritic cell subsets and CD4+ T cells J. Leukoc. Biol., May 1, 2005; 77(5): 777 - 786. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Chung, S. B. Amrute, K. Abel, G. Gupta, Y. Wang, C. J. Miller, and P. Fitzgerald-Bocarsly Characterization of Virus-Responsive Plasmacytoid Dendritic Cells in the Rhesus Macaque Clin. Vaccine Immunol., March 1, 2005; 12(3): 426 - 435. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mazzoni and D. M. Segal Controlling the Toll road to dendritic cell polarization J. Leukoc. Biol., May 1, 2004; 75(5): 721 - 730. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. Megjugorac, H. A. Young, S. B. Amrute, S. L. Olshalsky, and P. Fitzgerald-Bocarsly Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells J. Leukoc. Biol., March 1, 2004; 75(3): 504 - 514. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Izaguirre, B. J. Barnes, S. Amrute, W.-S. Yeow, N. Megjugorac, J. Dai, D. Feng, E. Chung, P. M. Pitha, and P. Fitzgerald-Bocarsly Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells J. Leukoc. Biol., December 1, 2003; 74(6): 1125 - 1138. [Abstract] [Full Text] |
||||
![]() |
K. Muller, S. Bischof, F. Sommer, M. Lohoff, W. Solbach, and T. Laskay Differential Production of Macrophage Inflammatory Protein 1{gamma} (MIP-1{gamma}), Lymphotactin, and MIP-2 by CD4+ Th Subsets Polarized In Vitro and In Vivo Infect. Immun., November 1, 2003; 71(11): 6178 - 6183. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||